MAPT and Alzheimer disease: To date, the diagnosis of AD is based on a time-consuming combination of psychological testing, imaging and the analysis of three well-established biomarkers [amyloid-β42 (Aβ42), total tau and phospho-tau-181] in cerebrospinal fluid (Blennow 2005; Humpel 2011a).